Advertisement
Screener

COMPASS THERAPEUTICS, INC. (CMPX) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

2.8 / 5 stars · 68/120 Roast Me

COMPASS THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

COMPASS THERAPEUTICS, INC. (CMPX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$7.90 thousand for the 12-month period ending 2020-03-31, per its 10-K filed 2020-06-08.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2020-06-08

  • COMPASS THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2020-03-31 was -$13.90K.
  • COMPASS THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-12-31 was $1.80K, a 5.88% increase year-over-year.
  • COMPASS THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-09-30 was $6.20K, a 3.33% increase year-over-year.
  • COMPASS THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-06-30 was -$2.00K.
  • COMPASS THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was -$7.90K.
  • COMPASS THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was -$7.60K.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 0 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month as first filedValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month as first filedValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month
2020-03-31-$13.90K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08
-$12.10K
derived: sum of 2 quarters · filed 2020-06-08
-$5.90K
derived: sum of 3 quarters · filed 2020-06-08
-$7.90K
10-K · filed 2020-06-08
2019-12-31$1.80K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14
$8.00K
derived: sum of 2 quarters · filed 2020-02-14
$6.00K
10-Q · filed 2020-02-14
-$7.30K
derived: sum of 4 quarters · filed 2020-06-08
2019-09-30$6.20K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-13
$4.20K
10-Q · filed 2019-11-13
-$9.10K
derived: sum of 3 quarters · filed 2020-06-08
-$7.40K
derived: sum of 4 quarters · filed 2020-06-08
2019-06-30-$2.00K
10-Q · filed 2019-08-13
-$15.30K
derived: sum of 2 quarters · filed 2020-06-08
-$13.60K
derived: sum of 3 quarters · filed 2020-06-08
-$7.60K
derived: sum of 4 quarters · filed 2020-06-08
2019-03-31-$13.30K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08
-$11.60K
derived: sum of 2 quarters · filed 2020-06-08
-$5.60K
derived: sum of 3 quarters · filed 2020-06-08
-$7.60K
10-K · filed 2020-06-08
2018-12-31$1.70K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14
$7.70K
derived: sum of 2 quarters · filed 2020-02-14
$5.70K
10-Q · filed 2020-02-14
-$5.70K
10-Q · filed 2019-02-14
2018-09-30$6.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-13
$4.00K
10-Q · filed 2019-11-13
-$4.00K
10-Q · filed 2018-11-14
2018-06-30-$2.00K
10-Q · filed 2019-08-13
2018-03-31-$7.40K
10-K · filed 2019-07-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Alector, Inc. (ALEC)United States$0.213B-1.90
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35